ECD not linked to CCT in keratoconus

Article

Corneal endothelial cell density (ECD) changes are independent from central corneal thickness (CCT) in keratoconus patients, states a recent paper.

Corneal endothelial cell density (ECD) changes are independent from central corneal thickness (CCT) in keratoconus patients, states a recent paper.

The cross-sectional controlled study, headed by Dr Ozgur Bulent Timucin, Van Training and Research Hospital, Department of Ophthalmology, Van, Turkey, prospectively assessed 65 keratoconus patients with no history of contact lens wear and 40 healthy control subjects. The Heidelberg Retinal Tomography Rostock Cornea Module (HRT3/RCM) was used to evaluate all eyes. The main outcome was the comparison of the average ECD from both groups.

The results revealed that 19 eyes had mild keratoconus, 21 had moderate keratoconus and 25 had severe keratoconus. The mean ECD was 2731.6 ± 303.2 cells/mm2 and 2664.9 ± 319.5 cells/mm2 in keratoconus patients and control subjects, respectively.

There were no differences betweens densities and no significant correlations between ECD and CCT or steepest keratometric. There were no changes in ECD in keratoconic patients without a history of contact lens use when compared to the healthy subjects.

Visit the Journal of the British Contact Lens Association.

Newsletter

Join ophthalmologists across Europe—sign up for exclusive updates and innovations in surgical techniques and clinical care.

Recent Videos
A photo of Seville, Spain, with the Congress on Controversies in Ophthalmology logo superimposed on it. Image credit: ©francovolpato – stock.adobe.com; logo courtesy COPHy
Anat Loewenstein, MD, Professor and Director, Department of Ophthalmology, Tel Aviv Medical Center, discusses the Congress on Controversies in Ophthalmology (COPHy)
Anat Loewenstein, MD, speaks about the 22nd Annual Angiogenesis, Exudation, and Degeneration Meeting in February 2025 and shares her global forecast for AI-driven home OCT
Sarah M. Thomasy, DVM, PhD, DACVO, a veterinary ophthalmologist at UC Davis, talks about how her research at the Glaucoma 360 symposium
I. Paul Singh, MD, an anterior segment and glaucoma specialist, discusses the Glaucoma 360 conference, where he participated in a panel discussion on the use of artificial intelligence (AI) in glaucoma care.
Charles Wykoff, MD, PhD, discusses his Floretina ICOOR presentation topic, retinal non-perfusion in diabetic retinopathy, with David Hutton, editor of Ophthalmology Times
Elizabeth Cohen, MD, discusses the Zoster Eye Disease study at the 2024 AAO meeting
Victoria L Tseng, MD, PhD, professor of ophthalmology and glaucoma specialist, UCLA
© 2025 MJH Life Sciences

All rights reserved.